FORM D
RECEIVED 2006

NITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL

OMB Number:

3235-0076

Expires:

April 30, 2008

Estimated average burden hours per response 16.00



| | 06040466 | | |
|---|---|--|--|
| Name of Offering (check if this is an amendment and name has changed, and indicate change.) Ordinary Shares and Promissory Notes | | | |
| Filing Under (Check box(es) that apply): Rule 504 Rule 505 Type of Filing: New Filing Amendment | ☐ Section 4(6) ☐ ULOE | | |
| A. BASIC IDENTIFICATION DATA | | | |
| Enter the information requested about the issuer | | | |
| Name of Issuer (☐ check if this is an amendment and name has changed, and indicate change.) NHS Pharmaceuticals | | | |
| Address of Executive Offices (Number and Street, City, State, Zip Code) c/o M&C Corporate Services Limited, P.O. Box 309GT, Ugland House, South Church St., George Town, Grand Cayman, Cayman Islands | Telephone Number (Including Area Code) 345-949-8066 | | |
| Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices) | Telephone Number (Including Area Code) | | |
| Brief Description of Business Marketing and sale of active pharmaceutical ingredients and finished product pharmaceuticals | PROCESSED | | |
| Type of Business Organization Corporation Ilimited partnership, already formed business trust limited partnership, to be formed other (p | JUL 2 1 2006 lease specify): | | |
| Actual or Estimated Date of Incorporation or Organization: Month Year 0 6 | ✓ Actual Estimated | | |
| Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service Abbreviation for CN for Canada; FN for other foreign jurisdiction) | State: F N | | |
| GENERAL INSTRUCTIONS | | | |
| Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or | Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. | | |

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6)

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1972 (6-02)



| | | A. BASIC IDENTIFICA | ATION DATA | | | | |
|--|-------------------------|------------------------------|-----------------------------|-------------------|-----------------------------------|--|--|
| Enter the information requested for the following Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issues; and Each general and managing partner of partnership issuers. | | | | | | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | ☑ Executive Officer | ☑ Director | General and/or Managing Partner | | |
| Full Name (Last name first, if ind Kung, Frank | ividual) | | | 377.4 | 3 0 | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) c/o NHS Pharmaceuticals, M&C Corporate Services Limited, P.O. Box 309GT, Ugland House, South Church St., George Town, Grand Cayman, Cayman Islands | | | | | | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | ☐ Executive Officer | ☑ Director | General and/or Managing Partner | | |
| Full Name (Last name first, if ind Yu, Chen | ividual) | | | | | | |
| Business or Residence Address (N | Number and Street, City | , State, Zip Code) | | | | | |
| c/o NHS Pharmaceuticals, M Cayman Islands | &C Corporate Service | es Limited, P.O. Box 309G | T, Ugland House, South | Church St., Georg | e Town, Grand Cayman, | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | ☐ Executive Officer | ☐ Director | ☐ General and/or Managing Partner | | |
| Full Name (Last name first, if ind Vivo Ventures Fund V, L.P. | ividual) | | | | | | |
| Business or Residence Address (N 575 High Street, Suite 201, Pa | - | y, State, Zip Code) | | | | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | ☐ Executive Officer | ☐ Director | ☐ General and/or Managing Partner | | |
| Full Name (Last name first, if ind | ividual) | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) | | | | | | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | ☐ Executive Officer | ☐ Director | General and/or Managing Partner | | |
| Full Name (Last name first, if ind | ividual) | | | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) | | | | | | | |
| Check Box(es) that Apply: | Promoter | ☐ Beneficial Owner | Executive Officer | Director | General and/or Managing Partner | | |
| Full Name (Last name first, if ind | ividual) | | 777 97 574 5 | | | | |
| Business or Residence Address (Number and Street, City, State, Zip Code) | | | | | | | |
| Check Box(es) that Apply: | Promoter | Beneficial Owner | Executive Officer | Director | ☐ General and/or Managing Partner | | |
| Full Name (Last name first, if individual) | | | | | | | |
| Business or Residence Address (N | Number and Street, City | , State, Zip Code) | | | | | |
| | (Use blank sheet | , or copy and use additional | copies of this sheet, as no | ecessary) | | | |

Page 2

A. BASIC IDENTIFICATION DATA Enter the information requested for the following Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issues; and Each general and managing partner of partnership issuers. ☐ Beneficial Owner ☐ Executive Officer ☐ General and/or Promoter ☐ Director Check Box(es) that Apply: Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ General and/or Check Box(es) that Apply: ☐ Director Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer ☐ Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) ☐ Beneficial Owner Check Box(es) that Apply: Promoter ☐ Executive Officer □ Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Check Box(es) that Apply: ☐ Promoter ☐ Beneficial Owner ☐ Executive Officer Director ☐ General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code)

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

| | | | | В. І | NFORMATI | ION ABOUT | OFFERING | 3 | | | | |
|-----------|--|--------------------------------|-----------------|-----------------|----------------|---------------|----------------|------------------|--------------|-------------|---------------------------------------|-------------|
| | | _ | | | | | | | | | Yes | No |
| 1. | Has the issuer sol | d, or does the | ssuer intend t | | | | _ | | | | | \boxtimes |
| | Answer also in Appendix, Column 2, if filing under ULOE. 2. What is the minimum investment that will be accepted from any individual? | | | | | | | | | | | |
| 2. | What is the minin | num investmer | it that will be | accepted from | n any individi | ual? | | | ••••• | | \$ <u>N/A</u> | No |
| 3. | Does the offering permit joint ownership of a single unit? | | | | | | | Yes □ | No ⊠ | | | |
| 4. 1 | Enter the informa | ation requested | for each per | son who has | been or will | be paid or g | iven, directly | or indirectly | , any commi | ssion or | _ | _ |
| ; (| similar remunerat associated person dealer. If more the for that broker or | or agent of a nan five (5) per | broker or dea | ler registered | with the SEC | C and/or with | a state or sta | ites, list the n | ame of the b | roker or | | |
| Full Na | me (Last name fi | rst, if individua | al) | | | | | | | | | |
| Busines | ss or Residence A | ddress (Numb | er and Street, | City, State, Z | ip Code) | | | | , | | | |
| Name o | of Associated Bro | ker or Dealer | | | | | | | | | | |
| States in | n Which Person L | isted Has Soli | cited or Inten | ds to Solicit I | Purchasers | | | | | | | |
| | (Check "All St | ates" or check | individuals S | tates) | | | | | | | □ A | II States |
| [AI | L] [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] |] [IN] | [IA] | [KS] | [KY] | [LA]] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [M | T] [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |
| Full Na | me (Last name fi | rst, if individua | al) | | | | | | | | · · · · · · · · · · · · · · · · · · · | |
| Busines | ss or Residence A | ddress (Numbe | er and Street, | City, State, Z | ip Code) | | | | | | | |
| Name o | of Associated Bro | ker or Dealer | | | | | | | | | | |
| States in | n Which Person I | isted Has Soli | cited or Inten | ds to Solicit F | Purchasers | | ··· | *** | | | | |
| | (Check "All St | ates" or check | individuals S | tates) | | | | | | | | Il States |
| [AI | L] [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL] |] [IN] | [IA] | [KS] | [KY] | [LA]] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [M | T] [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |
| Full Na | me (Last name fi | rst, if individua | al) | | | | | | | | | |
| Busines | s or Residence A | ddress (Numbe | er and Street, | City, State, Z | ip Code) | | | | | | · · · · · · · · · · · · · · · · · · · | |
| Name o | of Associated Bro | ker or Dealer | | | | · | | | | | | |
| States in | n Which Person L | Listed Has Soli | cited or Inten | ds to Solicit I | Purchasers | | | | | | | |
| | (Check "All St | ates" or check | individuals S | tates) | ••••• | | | | ••••• | | | Il States |
| [AI | L] [AK] | [AZ] | [AR] | [CA] | [CO] | [CT] | [DE] | [DC] | [FL] | [GA] | [HI] | [ID] |
| [IL |] [IN] | [IA] | [KS] | [KY] | [LA]] | [ME] | [MD] | [MA] | [MI] | [MN] | [MS] | [MO] |
| [M | T] [NE] | [NV] | [NH] | [NJ] | [NM] | [NY] | [NC] | [ND] | [OH] | [OK] | [OR] | [PA] |
| [RI | [SC] | [SD] | [TN] | [TX] | [UT] | [VT] | [VA] | [WA] | [WV] | [WI] | [WY] | [PR] |

(Use blank sheet, or copy and use additional copies of this sheet, as necessary)

Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged. Amount Already Aggregate Offering Price Sold Type of Security 2,499,900.00 2,499,900.00 Debt..... 100.00 100.00 Equity Preferred 0.00 0.00 Convertible Securities (including warrants) 0.00 0.00 Partnership Interests)..... 0.00 0.00 Other (Specify 2,500,000.00 \$ 2,500,000.00 Total Answer also in Appendix, Column 3, if filing under ULOE. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero." Aggregate Dollar Amount Number Investors of Purchase 2,500,000.00 Accredited investors..... 0_ 0.00 Non-accredited Investors N/A N/A Total (for filings under Rule 504 only) Answer also in Appendix, Column 4, if filing under ULOE. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1. **Dollar Amount** Type of Security Sold Type of Offering N/A 0.00 Rule 505..... Regulation A 0.00 N/A 0.00 N/A Rule 504 N/A 0.00 Total..... a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate. 0.00 П Transfer Agent's Fees 0.00 Printing and Engraving Costs..... Legal Fees 10,000.00 Accounting Fees.... 0.000.00 Engineering Fees 0.00 Sales Commissions (specify finders' fees separately)..... 0.00Other Expenses (identify) 10,000.00

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

b. enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." 2,490,000.00 Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C – Question 4.b above. Payments to Officers, Directors & Affiliates Payments to Others Salaries and fees..... □ \$ 0.00 □ \$_____ 0.00 Purchase of real estate □ \$____ 0.00 □ \$ ____. 0.00 Purchase, rental or leasing and installation of machinery and equipment..... □ \$___ 0.00 0.00 Construction or leasing of plant buildings and facilities..... □ \$_____ 0.00Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)..... □ \$ 0.00 0.00 Repayment of indebtedness 0.00 0.00 □ \$____ Working capital □ \$ 0.00 **■ \$** 2,490,000.00 ____ □ \$ 0.00 Other (specify): □ \$ 0.00 Column Totals..... □ \$ 0.00 **∑** \$____2,490,000.00

Total Payments Listed (column totals added).....

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

■ \$2,490,000.00

| D. | FED | ER. | ٩I | SIG | NA | TURE |
|----|-----|-----|----|-----|----|------|
| | | | | | | |

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

| Issuer (Print or Type) | Signature | Date | | | |
|--------------------------------|---------------------------------------|---------------|--|--|--|
| NHS Pharmaceuticals | 4 th | June 23, 2006 | | | |
| Name of Signer (Print or Type) | Title of Signer (Print or Type) | | | | |
| Frank Kung | President and Chief Executive Officer | | | | |

ATTENTION

Intentional Misstatements or Omissions of Fact Constitute Federal Criminal Violations. (See 18. U.S.C. 1001.)